-
Product Insights
NewLikelihood of Approval Analysis for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Overview How likely is it that the drugs in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview Transitional...
-
Product Insights
NewLikelihood of Approval Analysis for Basal Cell Carcinoma (Basal Cell Epithelioma)
Overview How likely is it that the drugs in Basal Cell Carcinoma (Basal Cell Epithelioma) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Basal Cell Carcinoma (Basal Cell Epithelioma) Overview Basal...
-
Track & Monitor
NewCell & gene therapy in pharma: corneal endothelial cell culturing
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s corneal endothelial cell culturing segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Product Insights
NewLikelihood of Approval Analysis for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Overview How likely is it that the drugs in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. T-Cell Acute Lymphocytic Leukemia (T-Cell Acute...
-
Product Insights
NewLikelihood of Approval Analysis for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Overview How likely is it that the drugs in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...
-
Innovation Ranking
NewInnovation Ranking – Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc (Lineage) formerly known as BioTime Inc, is a clinical-stage biotechnology company that develops new cell therapies for unmet medical needs. It develops products based on its core proprietary technology cell-based therapy platform. The company focuses on developing new cellular therapies for neurological conditions associated with demyelination and degenerative retinal diseases. Lineage’s lead product Renevia is developed for the treatment of facial lipoatrophy and HIV lipoatrophy. Its pipeline products include OpRegen for advanced dry age-related macular degeneration,...
-
Innovation Ranking
NewInnovation Ranking – BrainStorm Cell Therapeutics Inc
BrainStorm Cell Therapeutics Inc (BrainStorm Cell Therapeutics), formerly Golden Hand Resources Inc, is a biotechnology company which develops autologous stem cell therapies for neurodegenerative diseases. Its pipeline mesenchymal stem cell products are being developed based on cell therapy platform NurOwn, customized for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, parkinson’s disease, huntington’s disease, autism spectrum disorder, peripheral nerve injury and other indications. Its proprietary technology NurOwn induces mesenchymal stem cells to secrete high levels of neurotrophic factors to promote...
-
Product Insights
NewLikelihood of Approval Analysis for Merkel Cell Carcinoma
Overview How likely is it that the drugs in Merkel Cell Carcinoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Merkel Cell Carcinoma Overview Merkel cell carcinoma is a rare aggressive...
-
Product Insights
NewLikelihood of Approval Analysis for Sickle Cell Disease
Overview How likely is it that the drugs in Sickle Cell Disease will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sickle Cell Disease Overview Sickle cell anemia is a genetic (inherited)...
-
Product Insights
NewLikelihood of Approval Analysis for Stem Cell Transplantation
Overview How likely is it that the drugs in Stem Cell Transplantation will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Stem Cell Transplantation Overview Stem cell transplantation, also known as hematopoietic...